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Rationale: Remote ischemic perconditioning during cerebral ischemia (RIPerC) refers
to the application of brief episodes of transient limb ischemia commonly to a limb, it
represents a new safe, simple and low-cost paradigm in neuroprotection.
Aim and/or Hypothesis: To evaluate the effects of RIPerC on acute ischemic stroke
(AIS) patients, applied in the ambulance, to improve functional outcomes compared with
standard of care.
Sample Size Estimates:A sample size of 286 patients in each arm achieves 80%power
to detect treatment differences of 14% in the outcome, using a two-sided binomial test
at significance level of 0.05, assuming that 40% of the control patients will experience
good outcome and an initial misdiagnosis rate of 29%.
Methods and Design: We aim to conduct a multicentre study of pre-hospital RIPerC
application in AIS patients. A total of 572 adult patients diagnosed of suspected
clinical stroke within 8 h of symptom onset and clinical deficit >0 according to
prehospital rapid arterial occlusion evaluation (RACE) scale score will be randomized,
in blocks of size 4, to RIPerC or sham. Patients will be stratified by RACE score
scale. RIPerC will be started in the ambulance before hospital admission and
continued in the hospital if necessary. It will consist of five cycles of electronic
tourniquet inflation and deflation (5min each). The cuff pressure for RIPerC will
be 200 mmHg during inflation. Sham will only simulate vibration of the device.
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Study Outcome(s): The primary outcome will be the difference in the proportion of
patients with good outcomes as defined by a mRS score of 2 or less at 90 days.
Secondary outcomes to be monitored will include early neurological improvement
rate, treatment related serious adverse event rates, size of the infarct volume,
symptomatic intracranial hemorrhage, metabolomic and lipidomic response to RIPerC
and Neuropsychological evaluation at 90 days.
Discussion: Neuroprotective therapies could not only increase the benefits of available
reperfusion therapies among AIS patients but also provide an option for patients who are
not candidates for these treatments. REMOTE-CAT will investigate the clinical benefit of
RIC as a new neuroprotective strategy in AIS.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT03375762.
Keywords: ischemic stroke, remote ischemic perconditioning (rPerC), neuroprotection, infarct size (IS),
metabolomics (OMICS)
INTRODUCTION AND RATIONALE
Stroke is one of the leading causes of death worldwide and
the main cause of disability (1). Currently, the only therapies
for acute ischemic stroke (AIS) patients are the administration
of rt-PA (2) and/or endovascular treatment (3). Unfortunately,
many patients cannot benefit from these therapies due to
their contraindications or evolution time. Neuroprotective
therapies could not only increase the benefits of available
reperfusion therapies but also provide an option for patients
who are not candidates for these treatments (4). However,
most neuroprotection trials have so far failed to demonstrate
their efficacy in AIS patients, despite promising results in
animal studies (4). Remote ischemic perconditioning (RIPerC)
represents a new paradigm in neuroprotection (5). It potential
upregulates endogenous defense systems to achieve ischemic
tolerance in brain ischemia (6). It consists of brief episodes
of transient limb ischemia. According to studies in coronary
ischemia, RIPerC during the ischemic event is safe, feasible, and
related to a decrease in myocardial injury (7). However, there is
limited data about the clinical utility of RIPerC in AIS patients.
Only four randomized clinical trials (RCTs) have been completed
and published (8–11). All of them demonstrated that RIC is safe
and feasible in AIS. One has been conducted to test RIPerC in
a prehospital setting in AIS patients and as an adjunct treatment
with intravenous alteplase (11). Two other small-size studies were
only designed to evaluate the safety and feasibility of RIC in
AIS patients recruited within 24 h of onset of symptoms (8) and
in alteplase treated patients (9). The last and the largest study
included 188 patients with confirmed carotid ischemic stroke
within 6 h of symptoms onset (10). None of them demonstrated a
significant clinical effect or a significant effect on brain infarction
volume growth.
We aim to conduct a multicentre study of pre-hospital RIPerC
in AIS patients applied within 8 h of stroke onset. Our hypothesis
is that RIPerC would be safe and would induce endogenous
neuroprotective phenomena associated with good outcomes in
AIS patients treated with revascularization therapies or not.
METHODS
Design
REMOTE-CAT is a prospective randomized controlled
multicentre clinical trial that follows CONSORT statement
(12). The study will be performed in accordance with the
standards of good clinical practice (International committee on
Harmonization of E6 Guideline for Good Clinical Practice) and
the latest revision of the Declaration of Helsinki. The study has
been approved by the Ethics Committee on Clinical Research
of the Hospital Universitari Arnau de Vilanova of Lleida
(approval code 1744). All patients will provide written informed
consent. The protocol is registered in ClinicalTrials.gov identifier
is NCT03375762.
Patient Population
Inclusion and exclusion criteria are detailed in Table 1.
Summarizing, REMOTE-CAT focuses on patients with suspected
acute stroke identified in the pre-hospital setting by emergency
medical services (EMS). The EMS is a public company
responsible for urgent prehospital care including Code Stroke
(CS) patients. We will include consecutive adult subjects (age
≥18 years old) with CS activation will be included. CS activation
criteria include neurologic impairment suggestive of acute stroke
according to FAST criteria (13), time from symptom onset of
<8 h and previous functional independence (modified Rankin
Scale, mRS≤2). Patients should have at least motor impairment
(Figure 1). Baseline assessments and study procedures are
reported in Table 2.
Randomization
First, patients will be stratified using the rapid arterial occlusion
evaluation (RACE) scale score (14) and then, they will be
randomly allocated in blocks of size four, to either receive
remote ischemic conditioning (RIPerC group) or sham in the
ambulance. An on-call physician not involved in the study will
perform the randomization using a computer program located in
a web server.
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TABLE 1 | Inclusion and exclusion criteria.
Inclusion criteria
• Age above 18 years old
• Suspected clinical stroke within 8 h of onset of neurological symptoms
• Stroke code (SC) activation
• Independent in daily living before the acute onset of symptoms (mRs ≤ 2)
• RACE score>0 and RACE motor score>0
• Written informed consent (patient or legal representative)
Exclusion criteria
• Unknown onset of symptoms
• Coma (GCS< 8)
• Malignancy or significant comorbidity thought to limit life expectancy to <6
months
• Pregnancy
• Participation in other clinical trial related with a research
medical product/device
RACE, The rapid arterial occlusion evaluation scale; mRs, Modified Rankin scale; GCS,
Glasgow Coma Scale.
Intervention
RIPerC will consist of automatically delivered five cycles of
electronic tourniquet inflation to the upper non-paretic limb,
each lasting 5min and separated by 5min of cuff deflation.
The cuff will be inflated to 200 mmHg and it will be applied
to the opposite arm to the one experiencing motor and/or
sensory deficit in order to reduce the risk of phlebitis and to
maintain the somatosensory stimuli. RIPerC will be initiated
by the ambulance staff during transportation and it will be
finished for all patients in the ambulance or during Hospital
admission. All patients in both groups will be treated according to
conventional care procedures following international guidelines.
Thus, mechanical thrombectomy and intravenous fibrinolysis
will be allowed. Revascularization therapies will not be delayed
due to the study. The non-interventionist group will use a sham
device. It will simulate vibration of the device but no inflation will
be performed. Discomfort and complications related to RIPerC
will be recorded.
Primary Outcome
The primary outcome will be the difference in the proportion of
patients with good outcomes as defined by a mRS score of 2 or
less at 90 days.
Secondary Outcomes
The secondary outcomes will be: (1) a decrease in the National
Institutes of Health Stroke Scale (NIHSS) score greater or equal
than 4 between baseline and day one, 5 ± 1 days and 90
± 7 days; (2) a mRS score of 2 or less at 5 ± 1 days; (3)
the rate of serious adverse events related to the intervention;
(4) the rate of symptomatic intracerebral hemorrhage (SICH)
defined by the Safe Implementation of Thrombolysis in Stroke
Monitoring Study protocol at 24–36 hours (15); (5) acute
infarct volume; (6) metabolomic and lipidomic response to
RIC; and, (7) neuropsychological evaluation of cognitive and
affective domains.
In all eligible patients, a brain MRI will be performed within
3–4 days of the onset of symptoms, including the following
sequences: (1) transverse T2-FLAIR; (2) transverse T2∗-weighted
gradient-echo; (3) transverse diffusion-weighted (DWI) single-
shot echo-planar spin-echo; and, (4) axial 3D time-of-flight
MR angiography (through the circle of Willis). All participating
centers will follow the same protocol. A neuroradiologist blinded
to clinical features and intervention will review the MRI images.
Infarct volume will be defined as the hyperintense area on the
initial isotropic DWI acquired with a b value of 1,000 sec/mm2.
In addition, we will use metabolomic and lipidomic analyses
to define a panel of serum biomarkers accurately related to
RIC phenomenon. For these purposes, in 100 patients (50 sham
and 50 RIPerC), blood samples for further determination of
metabolomics and lipidomics will be drawn at arrival to hospital,
at days 3 and 5 as previously performed (16, 17). As we did not
have preliminary data and no metabolites have yet been defined
we will performed a non-targeted metabolomics and lipidomic
profiling in order to identify differential molecules found in the
intervention group.
The neuropsychological evaluation will include Montreal
cognitive assessment, trail making test part a and b, the Wechsler
adult intelligence scale, the free and cued selective reminding
test, the apathy evaluation scale and the Rey complex figure test.
We also performed the Health-related quality of life assessment
questionnaire (EQ-5D) at 90 days.
Data Monitoring Body
An independent data safety monitoring board (DSMB) will look
after the safety of the study. It will ensure that the rate of
SICH and serious adverse events is similar in the two groups.
An interim analysis will be performed after the inclusion of
the first 100 patients for early stopping due to safety reasons.
Moreover, the DSMB could recommend stopping the study for
safety reasons at any moment and make recommendations to the
Executive Committee regarding efficacy, quality and feasibility of
the study.
Sample Size Estimates
A sample size of 280 subjects in each arm achieves 80% power to
detect treatment differences of 14% between the intervention and
the control groups, using a two-sided binomial test at significance
level of 0.05, assuming that 40% of the control patients will
experience good outcome defined by a mRS score of 2 or less
at 90 days, and allowing a misdiagnosis rate of 29% (15% of
haemorrhagic strokes and 14% of mimic stroke conditions).
Two extra interim analyses will be performed at 33 and 67% of
recruitment on the primary outcome. Early stopping is planned
if large differences between the study groups are observed in
order to reduce study participants’ exposure to the inferior study
arm and saving time and resources. Since repeated significance
testing on accumulating data will be performed, adjustment of
the usual hypothesis testing procedure to maintain the overall
significance level of 0.05 will be done by using the flexible type
I error spending function (18, 19). Due to the interim analyses,
the sample size must be increased by an inflation factor of 1.02,
resulting in 572 patients (286 per group).
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FIGURE 1 | Graphical representation of REMOTE-CAT clinical trial procedures. After Stroke Code activation in the ambulance, remote ischemic perconditioning
(RIPerC) is applied by an automatic device during transportion to the nearest Stroke care center. Usual medical care will be performed in the stroke center.
Statistical Analyses
Included patients will be described with respect to demographic
and clinical characteristics, according to the study arm.
Continuous variables will be summarized using means and
standard deviations for normally distributed data; or median and
25–75% percentiles for non-normally distributed data. Normal
distribution will be assessed by means of the Shapiro–Wilks
test, rejecting normality when p < 0.05. Categorical data will
be summarized using counts and percentages. Comparisons will
be performed by means of the Pearson’s chi-squared test for
categorical variables; the t-test for normally distributed data; and
the Mann–Whitney U-test for non-normally distributed data.
Primary analysis will be performed by means of the binomial
test. If the study groups are unbalanced, the primary outcome will
be compared using a logistic regression model that will include
the variables exhibiting baseline differences as covariates.
Secondary outcomes will be compared using the most
appropriate test according to the distribution of the data. As with
the primary analysis, secondary outcomes and safety outcome
analyses will be conducted using multivariable generalized linear
models with suitable links.
The analysis will be performed on the intention-to-treat
set and will be repeated on the per-protocol set as a
sensitivity analysis.
Stratified Analysis
All objectives will be assessed in the following stratified
analyses: (i) by sex; (ii) depending on whether patients have
undergone thrombectomy; (iii) depending on whether patients
have undergone thrombectomy and treated with rtPA; (iv)
whether patients have undergone thrombectomy or treated with
rtPA; and (v) number of cycles of inflation and deflation finished
to evaluate a possible dose-response effect.
Handling Missing Data
If there are missing data, they will be reported for each variable
and missingness mechanism will be explored. Missing values
could depend on other observed data. We will consider these
missing values as missing at random (MAR). If there is no
correlation between the missing values and other observed data
(i.e., the Little’s test is not statistically significant, p > 0.05)
missing values will be considered missing completely at random
(MCAR) (20). If missing values are MAR, a series of multiple
imputations by chained equations will be performed and the
Rubin’s rules will be used to combine variable estimates and
standard errors (21). If missing values are MCAR, complete case
analysis will be performed.
Current Status of the Trial
The study started recruitment in August 2019 in one Hospital,
and the estimated completion date is August 2022. At 1st August
2020: 76 patients have been recruited.
Study Organization and Funding
FP is the coordinating investigator of the study, which is funded
by a grant from the Spanish National Ministry of Heath—
PI17/01725.
DISCUSSION
RIPerC emerges as an interesting neuroprotective strategy (5).
Our study improves the previous limited experience in humans
(8, 11). It includes all AIS with symptom onset within 8 h and
not only intravenous alteplase treated patients (11). According
to the animal model, it is effective when applied both alone
and in combination with revascularization therapies (22, 23).
Although few studies have been published about the effect of
RIC in AIS, some important issues have been learned (8–11).
As in Hougaard’s trial (11) and in most of the trials involving
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TABLE 2 | Study procedures for eligible patients with AIS.
Time points Prehospital Admission 24 h 3 days 5 days 3 months
Enrollment
Eligibility screen X
Patient/family information X X
Acute waiver of consent X
Randomization X
RACE scale X
Blood pressure X X‡
Informed consent X
AIS confirmation X* X*




Complications related to RIC X X X X
Assessment
NIHSS X X X X
Modified Rankin scale X X X
Neuroimaging X X#
MRI X
Blood biomarkers X X X
Stroke etiology X
Quality of life X
Neuropsychological evaluation X
Safety measurement
Intrahospital complications X X
SICH X X
RACE, rapid arterial occlusion evaluation; AIS, acute ischemic stroke; RIC, remote ischemic conditioning; MRI, magnetic resonance imaging; NIHSS, National Institutes of Health
Stroke Scale. ‡Blood pressure will be reported at the end of RIC/Sham application and 1 h after. *Patients with intracranial hemorrhage will complete the 90 days follow-up. Patients
without evidence of brain ischemia will be followed until discharge and through registries. #Patients treated with intravenous rtPA and/or EVT will undergo neuroimaging at 24 h.
patients with myocardial infarction (7, 24) it is applied it in
the ambulance, as soon as possible, in order to induce the
maximum effect. This action seems to be safe although the
definitive diagnosis will not be established until the arrival at the
hospital. To date, no serious adverse effects have been reported
in RIC studies (5, 7–11, 25). The recent RCT published by Pico
et al. failed to demonstrate an effect of RIC in the final infarction
size in AIS. One explanation of their neutral results was that
the treatment with RIC was performed too late during or after
the receipt of reperfusion therapies (10). In addition, we will
increase the number of cycles to five. Most RIC trials use the four-
cycle protocol (7, 11) due to tradition. The ischemic conditioning
phenomena was first demonstrated using this protocol in an
animal model of myocardial infarction (26). Recent studies in
animal models address the need to increase the number of
cycles in order to optimize the efficacy of RIPerC (27). Some
other recent successes in remote ischemic preconditioning (28)
and chronic postconditioning (29) in AIS patients have used
the 5-cycle protocol. Increasing the duration of the cycle to
10min does not offer any further protection (27). Although the
quantity of muscle mass affects the efficacy of the intervention,
we decided to perform the RIPerC on an upper arm rather
than on a leg for safety reasons as up to one in four AIS
patients have silent peripheral arterial disease defined by a low
ankle-brachial index (30). One of the main shortcomings of
the previously mentioned Hougaard’s trial (11) was that fewer
than one out of three patients complete the four cycles of
limb ischemia. We will therefore use an automatic device. To
avoid misdiagnosis only subjects with RACE score of >0 and
RACE motor items >0 will be included. Finally, according
to the stroke treatment academic industry roundtable (STAIR)
recommendations a clinical endpoint would clearly evaluate the
utility of applying RIPerC in AIS patients.
SUMMARY AND CONCLUSIONS
RIPerC represents a new paradigm in neuroprotection
with limited data in AIS patients. According to previous
preclinical and clinical studies of acute ischemia, a clinical
RIPerC trial should include both candidates and non-
candidates for reperfusion therapies. As the RIPerC effect
decreases with time, RIPerC should be started during
the transfer of stroke code patients. The size of the trial
should be large enough to detect differences in clinical
outcomes and not only neuroimaging endpoints. Finally,
the RIC device should be automatic to not only ensure that
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patients finish all of the programmed cycles but also to
interfere as little as possible with the work of paramedics
during the transfer and of nurses and physicians during
the admission.
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